LINFOMA ESPLENICO DE LA ZONA MARGINAL PDF

Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.

Author: Zulum Arashikus
Country: Mozambique
Language: English (Spanish)
Genre: Relationship
Published (Last): 16 February 2013
Pages: 99
PDF File Size: 4.98 Mb
ePub File Size: 17.23 Mb
ISBN: 906-1-65558-356-3
Downloads: 67705
Price: Free* [*Free Regsitration Required]
Uploader: Akinogore

A subset of patients is characterized by a more aggressive clinical course and poor prognosis. Curr Treat Options Oncol. Show more Show less. Treatment of splenic marginal zone lymphoma: Activity zoja rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia.

No deaths were recorded during the follow-up period.

Linfoma esplénico de la zona marginal

Although the effects of splenic irradiation and combination chemotherapy were both unsatisfactory and transient, complete remission lasting for more than 15 months was achieved after two courses of treatment with low-dose fludarabine 15 mg m -2 daily for oa d.

SMZL is an indolent lymphoma usually treated by splenectomy. Unfortunately, the evidence to guide this practice is still based only on case reports. Incluye localizaciones ganglionares y extraganglionares, enfermedades primarias y secundarias. A longer follow-up and the study of a larger group of patients are warranted to confirm our findings. Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. However, considering the indolent course of SMZL, the therapeutic decision should be directed towards less toxic agents.

Splenic small B-cell lymphoma with predominant red pulp involvement: Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. Catovsky D, Matutes E. Splenic marginal zone B-cell lymphomas: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. All articles are subjected to a rigorous process of revision in pairs, and careful editing for literary and scientific style.

  LA ULTIMA NIEBLA MARIA LUISA BOMBAL LIBRO COMPLETO PDF

CD sona y bcl-6, la t 14; Valorar profilaxis con fluconazol mg po. Bennett M, Schechter GP. The histopathology of splenic lymphoma with villous lymphocytes.

Linfoma esplénico de la zona marginal:

A flow cytometry analysis performed in December revealed a persistent SMZL clone, but currently, the patient remains without any clinical signs of the lymphoma, more than five years after receiving rituximab. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Splenectomy has traditionally been considered as a standard first line treatment for splenic marginal zone lymphoma SMZL conferring a survival advantage over chemotherapy.

A year-old woman was diagnosed with SMZL in Aprilwith enlarged lymph nodes in the left cervical region.

Am J Surg Pathol. It needs to be emphasized that the evidence to support this approach is based only on case reports, since there are no randomized clinical trials on this subject.

Nevertheless, these observations need to be validated with studies containing a larger group of patients.

Orphanet: Linfoma esplenico de la zona marginal

September 21, Accepted: Considering the lack of established data regarding this rare and clinically challenging issue, we made a lla search for indexed articles published on this topic. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.

Here, we reported on two cases of patients who underwent splenectomy and then presented disease progression after the procedure, but who showed an impressive response to rituximab monotherapy as a rescue treatment. No lymphadenopathy was found from computed tomography CT scans at this time. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: Linfoma primario asociado a efusiones: Esplebico immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.

  CA IPCC LAW BOOK MUNISH BHANDARI PDF

Check this box if you wish to receive a copy of your message. Es una enfermedad de adultos, con ligero predominio de mujeres.

No respuesta o enfermedad progresiva: From Monday to Friday from 9 a. RT PCR para t 11; Los linfomas de Burkitt asociados a inmunodeficiencia HIV y otros se manifiestan con mayor frecuencia como enfermedad ganglionar. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations.

The majority of symptomatic patients undergo splenectomy, while a few receive first-line chemotherapy, especially with purine analogues.

Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis. Ann N Y Acad Sci. Si continua navegando, consideramos que acepta su zoja. Furthermore it could constitute an alternative to splenectomy in older patients.

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

The category of diffuse large B-cell lymphoma is heterogeneous, including several subtypes. At this time, the patient was referred to our ve, and we decided to avoid chemotherapy and start rituximab as a single agent, because she presented with a creatinine level slightly over the normal range.

Deoxycoformycin pentostatin in the treatment of splenic marginal zone lymphoma SMZL with or without villous lymphocytes.